- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03092310
Feasibility Evaluation of an Artificial Pancreas With Glucose Prediction Trust Index
Feasibility Evaluation of an Artificial Pancreas With an Enhanced Model Predictive Control (eMPC) Controller and a Health Monitoring System (HMS) With a Glucose Prediction Trust Index
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a feasibility study of an artificial pancreas (AP) system with our previously validated target eMPC and HMS algorithms, with the addition of a trust index of the predicted glucose value integrated into the portable Artificial Pancreas System (pAPS). The system will be evaluated on up to 20 subjects, with the goal of 10 subjects completing a 48-hour closed-loop session at one clinical site (William Sansum Diabetes Center). During the session subjects will bolus for all meals and snacks and perform a 45-minute walking session.
The purpose of this pilot study is to establish that closed-loop insulin delivery with a target enchanted model predictive control (eMPC)/Health Monitoring System (HMS) algorithms with a trust index of the predicted glucose value is safe and effective, to analyze and learn to improve upon the accuracy of the predicted glucose values, and to collect efficacy data to inform a future larger study.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
California
-
Santa Barbara, California, Verenigde Staten, 93105
- William Sansum Diabetes Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥ 18 and ≤ 75 years at the time of screening.
- Clinical diagnosis of type 1 diabetes for at least one year.
- Has been using an insulin pump for at least 6 months at the time of screening.
- HbA1c < 10%, as performed by point of care or central laboratory testing. A1c will be assessed at the screening visit, or if already completed within 2 months of the screening visit, the prior lab value may be used in lieu of repeating this assessment.
- Serum creatinine of < 2.0 mg/dL. Serum creatinine will be assessed at the screening visit, or if already completed within 2 months of the screening visit, the prior lab value may be used in lieu of repeating this assessment.
- Bolus for all meals and snacks that contain ≥ 5 grams of carbohydrate.
- Willing to perform at least 7 fingerstick blood glucose tests a day.
- Willing to refrain from taking acetaminophen products for the duration of the clinical trial. If acetaminophen is taken, subject is to avoid making any insulin dosing decisions based on CGM for at least 12 hours.
- Willing to abide by the study protocol and use study-provided devices, including the Omnipod, Dexcom CGM, glucometer, ketone meter and pAPS tablet.
Exclusion Criteria:
- Pregnancy
- One or more episodes of hypoglycemia requiring an emergency room visit or hospitalization in the past 6 months.
- One or more episodes of hyperglycemia requiring an emergency room visit or hospitalization in the past 6 months.
- Known unstable cardiac disease or untreated cardiac disease, as revealed by history or physical examination.
- Dermatological conditions that would preclude wearing a CGM sensor or Pod.
- One or more seizures in the past year.
- Screening A1c ≥ 10% or serum creatinine ≥ 2.0 mg/dL.
- Any condition that could interfere with participating in the trial, based on investigator judgment.
- Concurrent use of any non-insulin glucose-lowering agent (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals), defined as using any of these medications within 30 days of the screening visit or during the study.
- Participation in another pharmaceutical or device trial at the time of enrollment or during the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Artificial Pancreas
The artificial pancreas device will employ its enhanced Model Predictive Control (MPC) algorithm with a target glucose level of 110 mg/dL with a trust index for MPC-predicted glucose values, weighing future glucose predictions and only acting on predictions with higher weight in the trust index.
The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values.
Using a redundant and independent algorithm is an important safety feature of the overall AP device.
|
Artificial Pancreas Device
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percent time within the target glucose range of 70-180 mg/dl overall as assessed by continuous glucose monitoring (CGM).
Tijdsspanne: 48 hours
|
The primary endpoint for this pilot study will be time within the target glucose range of 70-180 mg/dl overall as assessed by continuous glucose monitoring (CGM), during closed-loop use, determining if the combination of eMPC and the assessment of trust index can provide safe and effective glucose control.
|
48 hours
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Assessment of the trust index predictions vs. standard eMPC glucose predictions.
Tijdsspanne: 48 hours
|
During closed-loop use, assessment of the trust index predictions vs. standard eMPC glucose predictions (frequency of moving away from nominal weights of predicted glucose).
|
48 hours
|
Frequency of hypoglycemia during closed-loop use.
Tijdsspanne: 48 hours
|
Frequency of hypoglycemia during closed-loop use, defined as percent time glucose is below predefined thresholds of 70 mg/dl, 60 mg/dl and 50 mg/dL.
|
48 hours
|
Frequency of hyperglycemia during closed-loop use.
Tijdsspanne: 48 hours
|
Frequency of hyperglycemia during closed-loop use, defined as percent time glucose is above predefined thresholds of 180 mg/dl, 250 mg/dl, and 300 mg/dL.
|
48 hours
|
Percent time within the target glucose range of 70-140 mg/dl during closed-loop use.
Tijdsspanne: 48 hours
|
Percent time within the target glucose range of 70-140 mg/dl overall as assessed by continuous glucose monitoring (CGM), during closed-loop use.
|
48 hours
|
Percent time glucose is within range 70-150 mg/dl postprandial within 5 hours following meals, during closed-loop use.
Tijdsspanne: 48 hours
|
Percent time glucose is within range 70-150 mg/dl postprandial within 5 hours following meals, during closed-loop use.
|
48 hours
|
Standard Deviation and Coefficient of Variation of glucose values
Tijdsspanne: 48 hours
|
To measure glycemic variability, the standard deviation and coefficient of variation of glucose values (as measured by continuous glucose monitoring) will be determined during the 48 hours of closed-loop use.
|
48 hours
|
Markers of hypo- and hyperglycemia
Tijdsspanne: 48 hours
|
Markers of hypo- and hyperglycemia, to include LBGI (Low blood glucose index) and HBGI (High blood glucose index), during closed-loop use.
|
48 hours
|
Insulin Doses Given
Tijdsspanne: 48 hours
|
Change in total daily doses and post prandial insulin doses given during the 48 hours of closed-loop use.
|
48 hours
|
Number of treatments given for hypoglycemia (defined as carbohydrates given for treatment of a documented or suspected low blood sugar), during the 48 hours of closed-loop use.
Tijdsspanne: 48 hours
|
Treatments for hypoglycemia given during the 48 hours of closed-loop use.
Hypoglycemia treatments may be given in response to alerts from the HMS, if blood glucose < 70 mg/dL, or at the request of the subject or investigator.
|
48 hours
|
Number of alerts given by the HMS to prevent hypoglycemia
Tijdsspanne: 48 hours
|
Number of alerts given by the HMS to prevent hypoglycemia during closed-loop use.
|
48 hours
|
Failure analysis of the devices/connectivity issues that may occur (# disconnects and device restarts).
Tijdsspanne: 48 hours
|
Failure analysis of the devices/connectivity issues that may occur during closed-loop use.
This includes number of CGM communication losses with 3 or more missed points, and number of times the entire system required a restart.
|
48 hours
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Eyal Dassau, PhD, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University
- Hoofdonderzoeker: Francis J Doyle III, PhD, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University
- Hoofdonderzoeker: Alejandro Leguna, PhD, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- Pro00020556
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Diabetes mellitus type 1
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.VoltooidDiabetes mellitus, type 1 | Diabetes type 1 | Diabetestype1 | Diabetes mellitus type 1 | Auto-immuun diabetes | Diabetes Mellitus, insulineafhankelijk | Jeugddiabetes | Diabetes, auto-immuunziekte | Insulineafhankelijke diabetes mellitus 1 | Diabetes Mellitus, insulineafhankelijk, 1 | Diabetes Mellitus,... en andere voorwaardenVerenigde Staten
-
University of California, San FranciscoJuvenile Diabetes Research FoundationVoltooidDiabetes mellitus type 1 | Diabetes mellitus, type I | Insulineafhankelijke diabetes mellitus 1 | Diabetes Mellitus, insulineafhankelijk, 1 | IDDMVerenigde Staten, Australië
-
SanofiVoltooidDiabetes mellitus type 1 - Diabetes mellitus type 2Hongarije, Russische Federatie, Duitsland, Polen, Japan, Verenigde Staten, Finland
-
Capillary Biomedical, Inc.BeëindigdDiabetes type 1 | Diabetes mellitus type 1 | Diabetes mellitus, type I | Diabetes Mellitus, insulineafhankelijk, 1 | IDDMOostenrijk
-
Capillary Biomedical, Inc.VoltooidDiabetes mellitus, type 1 | Diabetes type 1 | Diabetes mellitus type 1 | Diabetes Mellitus, insulineafhankelijk, 1Australië
-
Spiden AGDCB Research AGWervingDiabetes mellitus type 1 | Diabetes mellitus type 1 met hypoglykemie | Diabetes mellitus type 1 met hyperglykemieZwitserland
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...OnbekendDiabetes mellitus type 1 met hyperglykemie | Diabetes mellitus type 1 met hypoglykemiePolen
-
Hoffmann-La RocheRoche DiagnosticsVoltooidDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Duitsland
-
AstraZenecaVoltooidDiabetes mellitus type 2 | Diabetes mellitus type 1Verenigde Staten
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)VoltooidDiabetes mellitus type 1 | T1DM | T1D | Nieuwe diabetes mellitus type 1Verenigde Staten, Australië
Klinische onderzoeken op Artificial Pancreas Device
-
Rabin Medical CenterVoltooidDiabetes type 1Israël, Duitsland, Slovenië
-
Sansum Diabetes Research InstituteJuvenile Diabetes Research FoundationVoltooidDiabetes mellitus type 1Verenigde Staten
-
SynCardia Systems. LLCGoedgekeurd voor marketing
-
Hospital Clinico Universitario de SantiagoWerving
-
Seoul National University HospitalOnbekendAlvleesklier fistelKorea, republiek van
-
Boston Scientific CorporationVoltooidRefractaire pancreaskanaalvernauwingen | Pijnlijke chronische pancreatitisBelgië
-
St. Antonius HospitalNog niet aan het wervenMicrobiële kolonisatie | Pancreas Adenocarcinoom | Periampullaire kanker | Kanker van de alvleesklier | Pancreas neoplasma | Periampullair carcinoom
-
Centre hospitalier de l'Université de Montréal...VoltooidColorectaal adenoom | Colorectale poliepCanada
-
Beijing Friendship HospitalVoltooidComplicatie van de behandeling | Duodenaal adenoomChina
-
Changhai HospitalPeking Union Medical College Hospital; Xuanwu Hospital, BeijingVoltooid